And let's say somehow our results in a much larger, placebo controlled trial are closer to Capricor's and show a decline, albeit less decline than placebo.
AFAIK, we are much further ahead on the regulatory path in the EMA than Capricor. So even if they beat us to market in the USA (and we get crowded out there), we still have the EMA markets. Less substantial growth potential for sure, but it wouldn't be a company killer.
And let's say somehow our results in a much larger, placebo...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
-0.001(1.32%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.7¢ | 7.5¢ | $38.88K | 514.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 39300 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 26315 | 1 |
View Market Depth
| Last trade - 15.19pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
-0.001 ( 1.27 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.8¢ | 7.5¢ | 112689 | ||
| Last updated 15.50pm 21/05/2024 ? | |||||
| PER (ASX) Chart |